Improved blood pressure control and use of renin-angiotensin-aldosterone system blockers have altered the clinical presentation or phenotype of chronic kidney disease (CKD) in U.S. adults with diabetes. These changes may influence mortality. 
urine albumin excretion (random urine albumin-to-creatinine ratio [ACR] $30 mg/g). Thus, population interventions that address CKD prevention may help mitigate diabetes-associated mortality.
Historically, the progression of CKD attributed to diabetes was presumed to follow a linear path, with transitions from normal urine albumin excretion (ACR ,30 mg/g) to moderately increased (ACR 30-300 mg/g), followed by severely increased urine albumin excretion (ACR .300 mg/g) based on studies conducted before the routine use of renin-angiotensinaldosterone system (RAAS) inhibitors. Only after urine albumin excretion becomes severely increased would eGFR then decline (6, 7) . However, as medical management of diabetes improved during the past three decades with increased use of RAAS inhibitors and better blood pressure and glucose control, the development of CKD in the setting of diabetes appeared more heterogeneous (8) . Concurrent with temporal changes in diabetes management, the frequency of increased urine albumin excretion has declined while low eGFR in the U.S. population with diabetes has increased and low GFR in the absence of increased urine albumin excretion has become more prevalent (9) . These dynamics in CKD clinical presentations or phenotypes, as defined by the eGFR and ACR in the U.S. population, are important because rates of cardiovascular disease, end-stage renal disease (ESRD), and mortality differ by these CKD phenotypes (10) (11) (12) .
Using data from the National Health and Nutrition Examination Surveys (NHANES), we examined temporal trends in the total deaths over 5 years by CKD phenotypes in the U.S. population with diabetes during years [1988] [1989] [1990] [1991] [1992] [1993] [1994] [1995] [1996] [1997] [1998] [1999] [2000] [2001] [2002] [2003] [2004] [2005] [2006] . We hypothesized that the proportion of deaths in the U.S. population with diabetes occurring in the setting of low GFR (eGFR ,60 mL/min/ 1.73 m 2 ) without increased urine albumin excretion (ACR ,30 mg/g) has increased over time. Information on the distribution of mortality in the U.S. population with diabetes may help guide population interventions for reducing morbidity and mortality in populations facing a rapid increase in diabetes incidence.
RESEARCH DESIGN AND METHODS
The NHANES are a multistage stratified probability sample of noninstitutionalized U.S. adults conducted by the National Center for Health Statistics to determine the health and nutritional status of the noninstitutionalized U.S. population. The NHANES were originally completed in 6-year periods, with the last 6-year survey completed during years [1988] [1989] [1990] [1991] [1992] [1993] [1994] After individuals with missing data on serum creatinine, urine ACRs, and mortality status, and individuals with ESRD (use of dialysis within the past 12 months) were excluded, a total of 1,834, 1,067, 1,160, and 1,781 sampled persons with diabetes were included in the analyses of NHANES for years 1988-1994, 1999-2002, 2003-2006, and 2007-2010 , respectively. The National Center for Health Statistics Institutional Review Board approved each NHANES cycle, and all participants provided written informed consent.
In each NHANES cycle, data were collected via a medical evaluation and participant interviews. The participant in terview collected self-reported data on age, race/ethnicity, sex, smoking status, history of a diagnosis of diabetes, heart failure, hypertension, myocardial infarction, angina, coronary heart disease, or stroke, as well as receipt of dialysis in the past 12 months or the use of antihypertensive or glucose-lowering medications.
CKD Phenotypes
NHANES participants completed standardized study visits conducted by trained study personnel following standardized protocols (13). Blood and urine samples were collected, processed, and transported to central laboratories following standardized protocols. Serum creatinine was calibrated according to published recommendations (14). The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation based on serum creatinine was used to calculate eGFR (15) , and low eGFR was defined as ,60 mL/min/1.73 m 2 . Urine albumin and creatinine were measured with a fluorescent immunoassay and Jaffe rate reaction, respectively. The eGFR ($90, 60-89, and ,60 mL/min/1.73 m 2 ) and ACR (,30, 30-300, and .300 mg/g) values were used to define nine eGFR-ACR groups or CKD phenotypes (16).
All-Cause Mortality
The NHANES data are linked with the National Death Index using probabilistic matching based on 12 identifiers for each participant. NHANES data from 1988 to 2006 were linked with the National Death Index to determine 5-year mortality. Mortality follow-up is available through 31 December 2011. The follow-up period for each participant was calculated as the interval between their NHANES evaluation and the data of death or 31 December 2011 for participants who did not die. As a result of the limited follow-up period, mortality rates were not examined for the 2007-2010 NHANES population.
Statistical Analyses
We used the svy suite of commands in Stata 14 software (StataCorp, College Station, TX) to account for the complex probability sample design and followed the NHANES analytical guidelines (17). Hence, all reported results take survey weights into account. Mortality rates were calculated using Stata's stptime function (using survey weights), which calculates persontime and incidence rates over groups. Population estimates of 5-year deaths in the U.S. population with diabetes and by CKD phenotype were determined by multiplying the observed mortality risk by the population estimate for that particular group. The proportion of deaths was calculated using the proportion function in Stata's svy suite. Age-standardized cumulative incidence of mortality over a 5-year period was determined by standardizing the age distributions of each time period to the 2000 U.S. population. Cox proportional hazards models were used to model mortality rates by time period for the population with diabetes, eGFR ,60 mL/min/ 1.73 m 2 , and ACR ,30 mg/g. Unadjusted models and models adjusted for age, sex, and race (model 1), comorbid conditions (model 2), and use of RAAS inhibitors and statins (model 3) were examined with the time period 1988-1994 as the referent.
RESULTS
The prevalence of diabetes in the U.S. population increased during the past three decades from 8.0% during years 1988-1994 to 11.8% during years 2007-2010 (47.5% relative increase). As a result of the growth of the U.S. population, the absolute number of U.S. adults with diabetes increased from 13.2 million during years 1988-1994 to 23.8 million during years 2007-2010 (80.3% relative increase). Table 1 summarizes the characteristics of the U.S. population with diabetes by time period. Overall, use of RAAS inhibitors and statin medications increased and systolic and diastolic blood pressures and serum LDL-cholesterol levels decreased over time, similar to findings in the general U.S. population. The mean age and waist circumference and the prevalence of hypertension, heart failure, and cancer have increased over time in the total U.S. population with diabetes (Table 1) .
Supplementary Tables 1 and 2 Fig. 1C) . Table 2 summarizes the characteristics of adults with diabetes and low eGFR and ACR ,30 mg/g by time period. The presence of comorbid conditions, such as heart failure and cancer, and use of RAAS inhibitors and statin medications have all increased over time in this group.
The crude and age-standardized 5-year mortality risks by CKD phenotype and by time period are reported in Table 3 . Temporal increases in the crude and agestandardized mortality risk were noted for adults with diabetes and low eGFR with ACR ,30 mg/g, whereas mortality risk generally decreased over time for those with low eGFR and ACR $30 mg/g. Figure 1 demonstrates the temporal changes in 5-year mortality rates in the total U.S. adult population with diabetes and in adults with diabetes and low eGFR by ACR groups. Mortality rates have overall declined for the total population of U.S. adults with diabetes and for those with diabetes and low eGFR with ACR $30 mg/g. However, the mortality rate in the CKD group with low eGFR and ACR ,30 mg/g increased from 35 deaths In unadjusted models, no significant association was noted between time period and mortality among U.S. adults with diabetes and low eGFR with ACR ,30 mg/g (see Supplementary Table 3) . Compared with years 1988-1994, hazard rates of mortality were higher for all later time periods for the adults with diabetes and low eGFR with ACR ,30 mg/g after adjustment for demographics and comorbidities, but differences did not meet statistical significance. Use of RAAS inhibitors and statin drugs attenuated these differences.
CONCLUSIONS
As a result of the increasing prevalence of low eGFR and decreasing prevalence of increased urine albumin excretion, the combined prevalence of low eGFR without increased urine albumin excretion in the U.S. population with diabetes has been increasing, as previously documented (9) . Low eGFR, defined as ,60 mL/min/ 1.73 m 2 , now affects nearly one in six U.S. adults with diabetes, or ;4.0 million, and more than half of adults with diabetes and low eGFR do not have increased urine albumin excretion. Our study demonstrates the potential effect that the CKD phenotype dynamics may have on mortality. Currently, more than one of every five deaths in the U.S. population with diabetes occurs in the setting of low eGFR with an ACR ,30 mg/g. Although mortality rates have trended downward for adults with diabetes and low eGFR with ACR $30 mg/g, mortality rates appear higher for those with eGFR ,60 mL/min/1.73 m 2 and ACR ,30 mg/g compared with rates during years 1988-1994. Consequently, the proportion of deaths in the U.S. population with diabetes associated with low eGFR and ACR ,30 mg/g has increased over time.
The reduction in albuminuria in diabetes is probably a reflection of the improved glycemic control and blood pressure control and the increased use of RAAS inhibitors during the past three decades (18) . Indeed, the use of RAAS inhibitors is dramatically higher and systolic and diastolic blood pressures are significantly lower in the later years in adults with diabetes and low eGFR with urinary ACR ,30 mg/g. These results are consistent with the earlier observations that the mortality and incidence of ESRD in diabetes (19) have been declining in recent years. With decreased mortality and decreased progression to ESRD, the prevalence of less advanced kidney disease in diabetes would be expected to increase, and the results of this study support that premise.
Over time, mortality rates have declined for most adults with diabetes who have increased urine albumin excretion. In contrast, mortality rates have not trended downward for individuals with low eGFR in the absence of increased urine albumin excretion, and these findings hold strong public health implications. Most clinical trials examining interventions to slow CKD progression in the setting of diabetes are limited to individuals with increased urine albumin excretion. Currently, we have few interventions that slow CKD progression in adults with diabetes in the absence of increased urine albumin excretion. The newer glucoselowering agents, such as sodium-glucose cotransporter 2 inhibitors and the glucagon like peptide 1 agonists, have demonstrated both renal and cardiovascular benefits in adults with diabetes and moderate CKD, and clinical trials included individuals without increased urine albumin excretion (20) (21) (22) . Use of these agents in the setting of moderate CKD (eGFR 59-30 mL/min/1.73 m 2 ) may not only slow eGFR decline but also reduce cardiovascular mortality.
This study also showed increases in the use of RAAS inhibitors and progressive lowering of average systolic and diastolic blood pressures during the past two decades among adults with diabetes. Some of these individuals with reduced eGFR in the absence of increased urine albumin excretion possibly have CKD due to reduced renal perfusion pressure from aggressive blood pressure reduction. These individuals with reduced eGFR in the absence of increased urine albumin excretion may reflect sicker individuals who would have had increased urine albumin excretion in the absence of aggressive blood pressure lowering and use of RAAS inhibitors.
A limitation of the study is that diabetic kidney disease is based on eGFR and ACR values. In some individuals, low eGFR in the absence of increased urine albumin excretion may be due to nondiabetes disease processes. However, studies have demonstrated the presence of classical pathologic lesions associated with diabetes in kidneys of adults with low eGFR in the absence of increased urine albumin excretion (23) (24) (25) . That low eGFR in the absence of increased urine albumin excretion may be due to tubulointerstitial disease caused by diabetes has also been hypothesized (26) . Thus, nondiabetic kidney diseases are not likely the cause of low eGFR in most adults with diabetes. Our study included a fasting glucose $126 mg/dL to define the presence of diabetes in addition to an elevated HbA 1c and/or use of glucose-lowering medications, whereas a previous analysis of diabetes in NHANES did not (9) . Differences in definition of diabetes may lead to small differences in prevalence estimates for CKD phenotypes defined by eGFR and ACR values. Our analysis focused on three eGFR groups and could not specifically focus on adults with more advanced CKD due to sample size limitations. Our analyses may also be inadequately powered to detect significant differences in mortality in the CKD group with eGFR ,60 mL/min/1.73 m 2 and ACR ,30 mg/g by time period due to the small number of sample participants. NHANES are multiple cross-sectional samples reflecting snap shots of the noninstitutionalized U.S. population at that given time period. Longitudinal follow-up data are not available in NHANES. Thus, we cannot determine whether the natural history of CKD development and progression differed within a given individual across time. However, we did show that the higher hazard rate for mortality in the earlier time period in this CKD group was attenuated after adjusting for differences in comorbid conditions and use of RAAS inhibitors during later time periods.
In summary, the phenotype or clinical presentation of CKD in the U.S. population with diabetes has evolved over time, and this change appears to have influenced mortality rates. The most common phenotype of kidney disease in diabetes is now low eGFR with ACR ,30 mg/g. Apart from targeting CKD progression in those with severely increased urinary albumin excretion (ACR .300 mg/g), clinical interventions and public health policies should also address the high mortality rates in adults with diabetes and low eGFR in the absence of increased urine albumin excretion.
